← Back to screener

Enliven Therapeutics, Inc. ELVN

Rank #2204 · Nasdaq · $2.7B market cap
Audited by Deloitte & Touche LLP, no going-concern flag in the latest filing.
Score
29.4
P/E
-30.3
P/B
10.96
ROE
-36.2%
Op. Margin
–%
Debt Ratio
6%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -30.3x, P/B 10.96x. Ranks in the top 78% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -36.2%. Ranks in the top 86% of the universe.

Safety ★★★★★
Excellent

Debt ratio 6%. Ranks in the top 9% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2020–$-0.0B$-0.0B$-0.0B–-17
2021–$-0.0B$-0.0B$-0.0B–-13
2022–$-0.1B$-0.1B$0.1B–9
2023–$-0.0B$-0.0B$-0.0B–-24
2024–$-0.1B$-0.1B$-0.1B–-34
2025–$-0.1B$-0.1B$0.2B–6

← See the full screener